ES2154299T3 - Metodos para la regulacion de la motilidad gastrointestinal. - Google Patents

Metodos para la regulacion de la motilidad gastrointestinal.

Info

Publication number
ES2154299T3
ES2154299T3 ES94927398T ES94927398T ES2154299T3 ES 2154299 T3 ES2154299 T3 ES 2154299T3 ES 94927398 T ES94927398 T ES 94927398T ES 94927398 T ES94927398 T ES 94927398T ES 2154299 T3 ES2154299 T3 ES 2154299T3
Authority
ES
Spain
Prior art keywords
methods
regulation
gastrointestinal motility
gastric emptying
inappropriate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94927398T
Other languages
English (en)
Inventor
Orville G Kolterman
Andrew A Young
Timothy J Rink
Kathleen Keiting Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2154299T3 publication Critical patent/ES2154299T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

SE DESCRIBEN METODOS PARA EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON NIVELES SANGUINEOS POST-PANDRIALES ELEVADOS INAPROPIADOS O NO DESEADOS QUE COMPRENDEN LA ADMINISTRACION DE UNA CANTIDAD EFECTIVA DE UN AGONISTA DE AMILINA SOLO O EN CONJUNCION CON OTROS AGENTES DE VACIADO ANTI-GASTRICO. TAMBIEN SE DESCRIBEN METODOS PARA REDUCIR LA MOVILIDAD GASTRICA Y RETRASAR EL VACIADO GASTRICO PARA PROPOSITOS TERAPEUTICOS Y DE DIAGNOSTICO.
ES94927398T 1993-09-07 1994-09-07 Metodos para la regulacion de la motilidad gastrointestinal. Expired - Lifetime ES2154299T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11838193A 1993-09-07 1993-09-07

Publications (1)

Publication Number Publication Date
ES2154299T3 true ES2154299T3 (es) 2001-04-01

Family

ID=22378228

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94927398T Expired - Lifetime ES2154299T3 (es) 1993-09-07 1994-09-07 Metodos para la regulacion de la motilidad gastrointestinal.

Country Status (23)

Country Link
US (4) US6114304A (es)
EP (1) EP0717635B1 (es)
JP (2) JP3821839B2 (es)
KR (2) KR100429966B1 (es)
CN (1) CN1134110A (es)
AT (1) ATE197549T1 (es)
AU (1) AU7685894A (es)
BG (1) BG100463A (es)
BR (1) BR9407424A (es)
CA (1) CA2171207C (es)
CZ (1) CZ69596A3 (es)
DE (1) DE69426304T2 (es)
DK (1) DK0717635T3 (es)
ES (1) ES2154299T3 (es)
GR (1) GR3035387T3 (es)
HU (1) HUT73490A (es)
NO (1) NO960899L (es)
PT (1) PT717635E (es)
RU (1) RU2177331C2 (es)
SG (1) SG98356A1 (es)
SK (1) SK31496A3 (es)
WO (1) WO1995007098A1 (es)
ZA (1) ZA946881B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
EP0717635B1 (en) * 1993-09-07 2000-11-15 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6143718A (en) 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
EP2016950B1 (en) 1996-08-08 2011-01-05 Amylin Pharmaceuticals, Inc. Pharmaceutical composition comprising an exendin-4 peptide
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
AU766653B2 (en) * 1998-02-13 2003-10-23 Amylin Pharmaceuticals, Inc. Novel mixed amylin activity compounds
US6936584B1 (en) 1998-02-13 2005-08-30 Amylin Pharmaceuticals, Inc. Mixed amylin activity compounds
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
ATE347901T1 (de) 1999-01-14 2007-01-15 Amylin Pharmaceuticals Inc Exendine zur glucagon suppression
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
US7399304B2 (en) 2000-03-03 2008-07-15 C.R. Bard, Inc. Endoscopic tissue apposition device with multiple suction ports
ES2435094T3 (es) 2000-05-19 2013-12-18 C.R. Bard, Inc. Dispositivo y método de captura y sutura de tejido
US6451813B1 (en) 2001-01-26 2002-09-17 R. T. Alamo Ventures I, Llc Treatment of gastroparesis in certain patient groups
WO2004024192A1 (en) * 2002-09-12 2004-03-25 University Of Chicago Monitoring and diagnosis of gastric emptying and gastroparesis
US8168233B2 (en) * 2002-10-18 2012-05-01 Amylin Pharmaceuticals, Inc. Treatment of pancreatitis with amylin
US7314859B2 (en) * 2002-12-27 2008-01-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) * 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
ATE471340T1 (de) 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8172857B2 (en) 2004-08-27 2012-05-08 Davol, Inc. Endoscopic tissue apposition device and method of use
EP2127676A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ATE439140T1 (de) 2005-03-31 2009-08-15 Amylin Pharmaceuticals Inc Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
JP5312054B2 (ja) 2006-03-15 2013-10-09 ノボ・ノルデイスク・エー／エス アミリンとインスリンの混合物
US20100004166A1 (en) * 2006-03-23 2010-01-07 Richard Pittner Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases
US20090181890A1 (en) * 2006-03-31 2009-07-16 Amylin Pharmaceuticals , Inc. Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders
US8309522B2 (en) 2007-02-05 2012-11-13 Amylin Pharmaceuticals, Llc Neuromedin and FN-38 peptides for treating psychiatric diseases
AU2007360979B2 (en) * 2007-11-14 2014-04-10 Amylin Pharmaceuticals, Llc Methods for treating obesity and obesity related diseases and disorders
NZ595021A (en) 2009-03-12 2013-04-26 Nordic Bioscience As Treatment of diabetes and metabolic syndrome with enteral formulations of calcitonin peptides or calcitonin receptor agonists
US8748375B2 (en) * 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
JP5969461B2 (ja) 2010-04-27 2016-08-17 ジーランド ファーマ アクティーゼルスカブ Ｇｌｐ−１受容体作動薬とガストリンとのペプチド複合体及びその使用
CA2853884A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
WO2014016300A1 (en) 2012-07-23 2014-01-30 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
BR112016008115B1 (pt) 2013-10-17 2024-03-12 Boehringer Ingelheim International Gmbh Análogos de glucagon acilados
BR112016009995B1 (pt) 2013-11-06 2023-04-18 Zealand Pharma A/S Compostos agonistas triplos glucagon-glp-1-gip
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015196174A1 (en) 2014-06-20 2015-12-23 Greene Howard E Infusion delivery devices and methods
JP6898231B6 (ja) 2014-10-29 2021-07-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐアゴニスト化合物及び方法
AU2016232218B2 (en) 2015-03-18 2020-09-10 Boehringer Ingelheim International Gmbh Amylin analogues
ES2763329T3 (es) 2015-04-16 2020-05-28 Zealand Pharma As Análogo de glucagón acilado
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
US10463717B2 (en) 2016-12-27 2019-11-05 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
SG11202000625PA (en) 2017-07-27 2020-02-27 Adocia Compositions in the form of an injectable aqueous solution comprising at least human insulin a21g and a prandial action glucagon suppressor
US11173109B2 (en) 2017-12-07 2021-11-16 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a co-polyamino acid
CA3084699A1 (en) 2017-12-07 2019-06-13 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin agonist receptor or an amylin analog and a co-polyamino acid
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
FR3083086A1 (fr) 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083085B1 (fr) 2018-06-29 2020-10-02 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
US20190275108A1 (en) 2017-12-07 2019-09-12 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analogue and a co-polyamino acid
FR3084586B1 (fr) 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451394A (en) * 1982-10-25 1984-05-29 American Home Products Corporation Dodecapeptides preventing glucose and triglyceride assimilation
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
US4690486A (en) * 1985-04-29 1987-09-01 Texas Instruments Incorporated Four position interlacing apparatus
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5166192A (en) * 1989-05-09 1992-11-24 Mathias John R Treatment of motility disorders with a GnRH analog
US5260275A (en) * 1990-08-14 1993-11-09 Amylin Pharmaceuticals, Inc. Hypoglycemics
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992020367A1 (en) * 1991-05-24 1992-11-26 Amylin Pharmaceuticals, Inc. Treatment of anorexia and related states
US5580953A (en) * 1991-08-14 1996-12-03 Amylin Pharmaceuticals, Inc. Amylin antagonist peptides and uses therefor
DK0567626T3 (da) * 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
WO1994020116A1 (en) * 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
EP0717635B1 (en) * 1993-09-07 2000-11-15 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists

Also Published As

Publication number Publication date
KR100391399B1 (ko) 2004-02-11
NO960899D0 (no) 1996-03-06
CA2171207C (en) 2010-03-30
WO1995007098A1 (en) 1995-03-16
DE69426304D1 (de) 2000-12-21
JP3821839B2 (ja) 2006-09-13
AU7685894A (en) 1995-03-27
US6114304A (en) 2000-09-05
RU2177331C2 (ru) 2001-12-27
JPH09502443A (ja) 1997-03-11
HU9600558D0 (en) 1996-05-28
DK0717635T3 (da) 2000-12-11
JP2004331674A (ja) 2004-11-25
HUT73490A (en) 1996-08-28
KR100429966B1 (ko) 2004-05-04
US7407934B2 (en) 2008-08-05
DE69426304T2 (de) 2001-03-15
SK31496A3 (en) 1998-06-03
KR20040004418A (ko) 2004-01-13
ATE197549T1 (de) 2000-12-15
EP0717635B1 (en) 2000-11-15
PT717635E (pt) 2001-04-30
CA2171207A1 (en) 1995-03-16
US20040097415A1 (en) 2004-05-20
US6608029B1 (en) 2003-08-19
CN1134110A (zh) 1996-10-23
EP0717635A1 (en) 1996-06-26
US5795861A (en) 1998-08-18
NO960899L (no) 1996-05-06
GR3035387T3 (en) 2001-05-31
SG98356A1 (en) 2003-09-19
BR9407424A (pt) 1996-04-09
ZA946881B (en) 1995-10-30
CZ69596A3 (en) 1997-06-11
BG100463A (en) 1997-03-31

Similar Documents

Publication Publication Date Title
ES2154299T3 (es) Metodos para la regulacion de la motilidad gastrointestinal.
CA2262647A1 (en) Methods for regulating gastrointestinal motility
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
NZ504258A (en) Exendin 3 and 4 agonist compounds for the treatment of diabetes
EP2295453A3 (en) An appetite-suppressing peptide, its compositions and use
ES2179096T3 (es) Utilizacion de la interleucina-12 para prevenir la reaccion del injerto contra el huesped.
GR880300072T1 (en) Bone fixation plate assembly provided with sutures
DE69435137D1 (de) Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
AU5220098A (en) Compositions and methods for enhancing intestinal function
BR9809951A (pt) Método para tratamento da obesidade
GR3031250T3 (en) Methods of diagnosing and treating preeclampsia
NO970533D0 (no) Blodbehandlingssystem og fremgangsmåte som overvåker citratretur til giveren
EP1383529A4 (en) METHOD FOR THE TREATMENT OF EYES AND SQUATING TISSUES WITH THYMOSINE 4 (T 4), ANALOGUE, ISOFORMS AND OTHER DERIVATIVES
ES2168384T3 (es) Derivados de 2-amino-1,2,3,4-tetrahidronaftaleno activos para el sistema cardiovascular.
UA50761C2 (uk) Спосіб запобігання та/або лікування серцевих захворювань, фармацевтична композиція та спосіб запобігання та/або лікування серцевої недостатності та дисфункції шлуночків в організмі теплокровної тварини
CA2229010A1 (en) Mannose-6-phosphate analogues for the treatment of wounds and fibrotic disorders with reduced scarring
NO894008D0 (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
WO1992018536A3 (en) Method for detecting an localizing tissues having neurokinine 1 receptors
DE3378979D1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
PT979098E (pt) Metodo para o tratamento da hiperprolactinemia e de prolactinomas
ZA832491B (en) Hydantoin therapeutic agents
DE69614577D1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
Kull Kollokvium „The Human Being at the Intersection of Science, Religion, and Medicine “
池田健彦 Stellate ganglion block activates muscle sympathetic nerve activity in the tibial nerve in humans

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 717635

Country of ref document: ES